Flash Finance

Venus Remedies LimitedVENUSREMCorporate

Pharmaceuticals - Indian - Formulations Latest results: Jun 2026 14 quarters of data
Consolidated Standalone
₹1,650.70
MCap ₹2,209 Cr · P/E 19.6
Venus Remedies Limited — Stock analysis & AI research Venus Remedies Limited — Seasonality — best & worst months Venus Remedies Limited — Technical indicators & charts Venus Remedies Limited — Technical setup — score, trend, support & resistance Venus Remedies Limited — Live exchange announcements
📋 High ROCE Stocks📋 High Interest Coverage Stocks📋 High Profit Growth Stocks📋 Stocks With Strong Quarterly Results📋 GARP Stocks (PEG Below 1)📋 Low Debt Stocks 📈 MACD Bearish Crossover📈 Bullish EMA Alignment📈 Multi-Timeframe Bullish Stocks 🏭 Pharma sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹179 Cr
Sales · Jun 2026
+35.6% YoY
₹37 Cr
Operating Profit · Jun 2026
+189.2% YoY
20.4%
OPM % · Jun 2026
+112.5% YoY
₹26 Cr
Net Profit · Jun 2026
+118.4% YoY
₹19.10
EPS · Jun 2026
+118.3% YoY

📝 Venus Remedies Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Venus Remedies Limited reported revenue of ₹179 crore for the quarter ended June 2026 (Q1 FY27), up 35.6% from ₹132 crore in the same quarter last year, and down 31.0% sequentially over the March 2026 quarter.

Net profit rose 118.4% year-on-year to ₹26 crore, from ₹12 crore. Earnings per share (EPS) came in at ₹19.10.

Operating profit stood at ₹37 crore — an operating margin (OPM) of 20.4%, compared with 9.6% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Venus Remedies Limited posted revenue of ₹764 crore, a growth of 19.4% over FY25, with a net profit of ₹99 crore (up 87.5% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹811 crore with a net profit of ₹112 crore.

Valuation snapshot

At the current price of ₹1,650.70, VENUSREM has a market capitalisation of ₹2,209 crore and a trailing P/E of about 19.6.

Within the Pharmaceuticals - Indian - Formulations industry, it is the 7th-largest of the 20 companies we track by market value.

Shareholding pattern

As of Sep 2026, promoters held 41.76%, foreign institutional investors (FIIs) 3.14%, domestic institutional investors (DIIs) 0.74%, public shareholders 54.36% of Venus Remedies Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹2,209 Cr
Current Price ?
₹1,650.7
P/E ?
19.65below ind
Industry P/E ?
21.30
P/B ?
3.21
P/S ?
2.72
P/FCF ?
19.38
Enterprise Value ?
₹2,221 Cr
EV/EBITDA ?
13.69
PEG ?
0.39
Earnings Yield ?
6.1%
Dividend Yield ?
0.00%
Profitability & Returns
Sales (TTM) ?
₹811 Cr
OPM ?
20.0%
Profit after tax (TTM) ?
₹112 Cr
EPS (TTM) ?
₹84.03
ROCE ?
20.0%
ROE ?
16.3%
ROA ?
12.8%
Growth
Sales — latest qtr ?
₹179 Cr
PAT — latest qtr ?
₹26 Cr
YoY qtr sales growth ?
35.6%
YoY qtr profit growth ?
118.4%
Sales growth (3y) ?
13%
Sales growth (5y) ?
9%
Profit growth (3y) ?
51%
Profit growth (5y) ?
26%
Financial Health
Debt ?
₹12 Cr
Debt to Equity ?
0.02
Interest Coverage ?
N/A
Current Ratio ?
N/A
Ownership
Promoter holding ?
41.76%
Change in promoter holding ?
0.00%
Pledged percentage ?
N/A
Market
Return 3 months ?
-6.7%
Return 6 months ?
58.7%

🗓️ Quarterly results (14 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 14999170131175106167173194132193180259179 +35.6% -31.0%
Operating Profit 2113131321141023231330375937 +189.2% -38.0%
Other Income 323242112782253 -68.1% -49.0%
Interest 0000000000000— — —
Depreciation 87666665466677 +9.4% -7.0%
Profit Before Tax 16810919101529251526335833 +121.8% -43.8%
Net Profit 8458134924151219254326 +118.4% -40.6%
EPS 5.643.254.086.139.363.336.9218.0211.078.7514.3918.6432.5119.10 +118.3% -41.2%
OPM % 14.1% 13.1% 7.6% 9.9% 12.1% 13.5% 6.1% 13.3% 11.6% 9.6% 15.5% 20.4% 22.8% 20.4% +112.5% -10.5%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹639 Cr ₹764 Cr ₹811 Cr +19.4%
Operating Profit ₹70 Cr ₹138 Cr ₹162 Cr +97.6%
OPM % 10.95% 18.11% 20.02% +65.4%
NPM % 8.22% 12.91% 13.87% +57.1%
Other Income ₹21 Cr ₹17 Cr ₹12 Cr -16.2%
Depreciation ₹22 Cr ₹25 Cr ₹26 Cr +16.9%
Interest ₹0 Cr ₹0 Cr ₹0 Cr —
EBIT ₹48 Cr ₹113 Cr ₹136 Cr +133.7%
PBT ₹79 Cr ₹132 Cr ₹149 Cr +66.3%
Tax ₹26 Cr ₹11 Cr ₹15 Cr -58.9%
Net Profit ₹53 Cr ₹99 Cr ₹112 Cr +87.5%
EPS ₹39.34 ₹74.29 ₹84.64 +88.8%
Material Cost ₹374 Cr ₹169 Cr ₹180 Cr -54.7%
Employee Cost ₹72 Cr ₹39 Cr ₹42 Cr -45.7%
Extraordinary Items ₹10 Cr — — —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 13131313 +0.0%
Reserves 465495576676 +17.4%
Borrowings 3939012 —
Other Liabilities 9294124174 +40.3%
Total Liabilities 609641713876 +22.9%
Fixed Assets 200203214215 +0.5%
CWIP 26212651 +96.2%
Investments 201984238 +183.3%
Other Assets 363398388372 -4.1%
Total Assets 609641713876 +22.9%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 283583151 +81.9%
Cash from Investing Activity -51-7-76-182 -139.5%
Cash from Financing Activity 000-1 —
Net Cash Flow -23287-32 -557.1%
Free Cash Flow 202365114 +75.4%
CFO/OP 46%84%140%129% -7.9%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 58575755 -3.5%
Inventory Days 12312298122 +24.5%
Days Payable 535467104 +55.2%
Cash Conversion Cycle 1291268873 -17.0%
Working Capital Days 11812997104 +7.2%
ROCE % 8%9%12%20% +66.7%

👥 Shareholding (latest 5 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026Sep 2026 % Chg
Promoters 41.76%41.76%41.76%41.76%41.76% +0.0%
FIIs 2.25%1.86%2.25%2.80%3.14% +12.1%
DIIs 0.11%0.75%1.03%1.20%0.74% -38.3%
Public 55.89%55.62%54.95%54.24%54.36% +0.2%
No. of Shareholders 19,30717,72518,60618,40322,968 +24.8%

⚖️ Peer comparison

Industry: Pharmaceuticals - Indian - Formulations · 20 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 SHILPAMED Shilpa Medicare ₹1,032.00 20,184 67.5 1,683 297 28.4% 17.7% 47.7% 454.9% 44.9% 115.2%
2 MARKSANS Marksans Pharma ₹332.50 15,068 29.1 3,171 521 22.5% 16.4% 12.5% 9.7% 35.6% 174.8%
3 BLISSGVS Bliss GVS ₹680.50 7,236 52.9 1,005 142 19.7% 14.1% 14.4% 48.7% 37.6% 15.8%
4 JSLL Jeena Sikho ₹507.55 6,309 26.7 852 236 42.6% 27.7% 17.1% 85.5% 28.8% 28.0%
5 SENORES Senores Pharmaceuticals ₹1,327.50 6,114 46.6 692 131 29.5% 19.0% 63.0% 108.7% 30.6% 43.8%
6 WINDLAS Windlas Biotech ₹1,129.50 2,331 35.7 942 66 11.1% 7.1% 18.9% 9.0% 18.1% -0.1%
7 VENUSREM Venus Remedies ₹1,651.10 2,210 19.0 811 117 20.4% 14.4% 17.9% 127.9% 35.6% 139.3%
8 SYNCOMF Syncom Formulations ₹23.44 2,203 1.3 12,547 1,729 15.2% 13.8% 2566.9% 3386.8% 7.4% 57.7%
9 HESTERBIO Hester Biosciences ₹2,187.90 1,861 13.6 318 137 30.8% 43.0% 4.7% 101.2% -8.4% 460.8%
10 AMRUTANJAN Amrutanjan Health ₹489.00 1,413 26.2 512 54 14.4% 10.5% 11.0% 1.3% 9.5% -45.4%
11 LINCOLN Lincoln Pharmaceuticals ₹601.50 1,205 12.5 694 97 14.6% 14.0% 7.6% 7.2% 15.1% 30.9%
12 BAFNAPH Bafna Pharmaceuticals ₹301.45 713 91.6 143 8 8.2% 5.5% 3.3% 166.8% -23.2% -97.8%
13 KILITCH Kilitch Drugs ₹198.00 692 16.1 237 29 15.3% 12.3% 18.7% 20.1% 4.0% -13.0%
14 MEDICAMEQ Medicamen Biotech ₹323.80 439 1.3 9,516 381 10.1% 4.0% 5751.8% 3308.0% 11.3% 15.3%
15 QUESTLAB Quest Laboratories ₹137.50 225 13.7 150 16 12.7% 11.0% 25.8% 34.9% -30.2% 47.9%
16 JFLLIFE Jfl Life ₹51.05 168 24.7 131 7 9.1% 5.2% 60.2% 53.1% -4.2% 48.5%
17 ZENITHDRUG Zenith ₹78.45 135 41.7 171 4 7.0% 2.3% — — 40.9% 100.0%
18 ALPA Alpa Laboratories ₹62.32 131 29.6 111 4 1.7% 4.0% -5.9% -22.5% 25.2% -91.7%
19 MEDIORG Medicamen ₹101.45 119 — 22 -3 -12.9% -14.0% — — -77.5% -383.0%
20 BIOFILCHEM Biofil Chemicals ₹33.13 54 110.4 34 0 2.3% 1.4% -15.0% 405.5% 92.1% -95.5%
❓ Frequently asked questions
What was Venus Remedies Limited's revenue in Q1 FY27?
Venus Remedies Limited reported revenue of ₹179 crore for the quarter ended June 2026 (Q1 FY27), up 35.6% from ₹132 crore in the same quarter last year, and down 31.0% sequentially over the March 2026 quarter.
What was Venus Remedies Limited's net profit in Q1 FY27?
Net profit rose 118.4% year-on-year to ₹26 crore, from ₹12 crore. Earnings per share (EPS) came in at ₹19.10.
What is VENUSREM's market capitalisation and P/E ratio?
At the current price of ₹1,650.70, VENUSREM has a market capitalisation of ₹2,209 crore and a trailing P/E of about 19.6.
Who owns Venus Remedies Limited? (shareholding pattern)
As of Sep 2026, promoters held 41.76%, foreign institutional investors (FIIs) 3.14%, domestic institutional investors (DIIs) 0.74%, public shareholders 54.36% of Venus Remedies Limited.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI